查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
到 2030 年笔式註射器市场预测：按类型、剂量、治疗、配销通路、最终用户和地区进行的全球分析
市场调查报告书
商品编码
1383444

到 2030 年笔式註射器市场预测：按类型、剂量、治疗、配销通路、最终用户和地区进行的全球分析

Pen Injectors Market Forecasts to 2030 - Global Analysis By Type (Disposable and Reusable), Dosage (Fixed Dosage, Variable Dosage, Half-Unit Dosage, Specialized Dosage and Other Dosages), Therapy, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球笔式註射器市场规模为 488.2 亿美元，预计在预测期内年复合成长率为 9.2%，到 2030 年将达到 758.1 亿美元。

笔式註射器是医疗设备，旨在为患者给药精确剂量的药物。它通常用于自行注射各种类型的药物，例如胰岛素、生长激素、某些生物製药和其他注射。笔式註射器广泛被患有糖尿病、多发性硬化症和类风湿性关节炎等慢性疾病的患者使用。笔式註射器的设计易于使用，使患者能够轻鬆处理和给药，而无需专业的医疗帮助。

Caspersen等人的数据显示，2020年美国约有1,090万65岁及以上的人被诊断出患有糖尿病，预计到2050年将达到2,670万人。

生物製药的进展

由于其复杂的分子结构和作用机制，生物製药通常需要精确的给药。笔式註射器适用于生物製药，因为它们旨在提供准确和稳定的给药。笔式註射器还允许患者自我给药生物製药製剂，从而减少频繁前往医疗机构的需要。此外，笔式註射器的便利性和易用性提高了患者对处方生物製药的依从性和医嘱遵从性，从而推动了市场需求。

与某些药物的相容性有限

如果笔式註射器与多种药物不相容，医疗保健提供者可能会犹豫是否开立或推荐笔式註射器。需要多种药物的患者可能会发现使用不同的给药方法既不方便又麻烦，因为有些药物与笔式註射器不相容。这可能会导致患者满意度和依从性降低。製造商可能会错失与製药公司的商机。这可能会导致失去合作伙伴关係和合约。

与数位健康解决方案集成

笔式註射器和数数位健康解决方案的集成为患者和医疗保健提供者提供了多种好处和应用。这使得患者能够追踪和监控他们的药物剂量。数位健康平台可以向患者发送提醒和警报，提醒他们按规定时间服药。根据收集的资料，医疗保健提供者可以就滴定和调整药物剂量做出资讯的决定，以最佳化治疗结果。此外，它还透过提高患者参与度、减少住院率和提供对特定症状的洞察来促进市场成长。

与替代药物输送的竞争

替代药物传递方法为患者提供了多种选择，包括口服锭剂、吸入器、贴剂，甚至智慧药丸和植入式设备等新技术。有些患者可能更喜欢替代的药物输送方法而不是笔式註射器，因为他们害怕针头。此外，根据您的症状，吸入或口服药物可能比注射药物更好。此外，技术创新和替代方案的改进对患者和医疗保健提供者越来越有吸引力，阻碍了市场成长。

COVID-19 的影响

笔式註射器市场是医疗设备产业的一部分，在大流行期间可能会经历正面和负面的影响。大流行期间远端医疗和远端监测的兴起可能影响了笔式註射器的采用，以帮助慢性病的自我给药和远端监测。经济不确定性和医疗保健优先事项的转变可能导致市场整合。这种流行病正在影响疫苗接种率和新流感病毒株的出现。

预计糖尿病领域在预测期内将是最大的领域。

糖尿病领域预计将出现良好的成长。笔式註射器可以准确且精确地给药胰岛素，确保个人获得正确剂量的药物。笔式註射器结构紧凑、重量轻且易于携带，对于需要在旅途中给药胰岛素的人来说非常方便。由于它使用细规格针头，因此註射过程中的疼痛和不适较少。其易用性、可客製化的给药和谨慎的给药正在推动这一领域的需求。

预计居家照护产业在预测期内年复合成长率最高。

由于其便利性和有效性，预计家庭护理设置行业在预测期内将实现最高的年复合成长率。笔式註射器的设计易于使用，并且通常具有简单的装载和给药机制。结构紧凑、便于携带，患者可以在家中或旅途中给药。这使得患者能够管理自己的药物治疗。这些因素正在推动该细分市场的成长。

比最大的地区

由于慢性病的增加和医疗保健支出的增加，预计亚太地区在预测期内将占据最大的市场占有率。中国、日本、印度、韩国和澳洲等国家由于人口众多且多样化，成为医疗保健产品和设备的主要市场。赛诺菲、诺和诺德和太阳製药等主要企业都位于该地区。此外，亚太地区的多个政府已实施政策和倡议来促进先进医疗设备的使用，这对笔式註射器市场产生了积极影响。

复合年复合成长率最高的地区：

由于慢性病的增加、自我给药的趋势以及笔式註射器技术的进步，预计北美在预测期内将呈现最高的年复合成长率。糖尿病盛行率的增加和肥胖人口的增加正在推动市场的成长。几家主要企业在这个市场上竞争，包括 Antares Pharma 和 Becton, Dickinson & Company。此外，技术进步、广泛的分销网络的存在以及需要更安全的输送设备的老年人口的增加是推动北美市场的其他因素。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球笔式註射器市场：按类型

  • 一次性的
  • 可重复使用的

第6章全球笔式註射器市场：按剂量

  • 固定剂量
  • 可变给药
  • 半单位给药
  • 特殊给药
  • 其他剂量

第7章全球笔式註射器市场：依处理方式

  • 糖尿病
    • 胰岛素
    • 胰高血糖素样胜胜肽-1 (GLP-1)
  • 生长激素
  • 骨质疏鬆症
  • 生育能力
  • 关节炎
  • 癌症
  • 多发性硬化症
  • 自体免疫疾病
  • 过敏反应
  • 心血管疾病
  • 其他治疗方法

第8章全球笔式註射器市场：按配销通路

  • 医院药房
  • 零售药房
  • 网路商城
  • 药局

第9章全球笔式註射器市场：依最终用户分类

  • 家庭护理设置
  • 医院和诊所

第10章全球笔式註射器市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第11章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第12章公司简介

  • AstraZeneca
  • Becton, Dickinson and Company
  • Merck Group
  • Pfizer Inc.
  • Eli Lilly and Company
  • Novartis AG
  • Sanofi
  • Novo Nordisk A/S
  • Biocon
  • Medtronic
  • Terumo Medical Corporation
  • Sun Pharmaceutical Industries Limited
  • GlaxoSmithKline PLC
  • Mylan NV
  • Novo Nordisk
  • Owen Mumford Limited
  • Phillips-Medisize
Product Code: SMRC24293

According to Stratistics MRC, the Global Pen Injectors Market is accounted for $48.82 billion in 2023 and is expected to reach $75.81 billion by 2030 growing at a CAGR of 9.2% during the forecast period. Pen injectors are medical devices designed to administer precise doses of medication to patients. They are often used for self-injection of various types of medication, including insulin, growth hormones, certain biologic drugs, and other injectables. Pen injectors are widely used by patients with chronic conditions such as diabetes, multiple sclerosis, rheumatoid arthritis, and more. They are designed to be user-friendly, making them easy for patients to handle and administer their medication, even without professional medical assistance.

According to Caspersen et al, in 2020, about 10.9 million people aged above 65 years were estimated to have been diagnosed with diabetes in the U.S, and this number is projected to reach 26.7 million by 2050.

Market Dynamics:

Driver:

Increasing advancements in biologic therapies

Biologic therapies often require precise dosages due to their complex molecular structures and mechanisms of action. Pen injectors are designed to deliver accurate and consistent dosages, making them well-suited for biologic medications. Also, Pen injectors enable patients to self-administer their biologic therapies, reducing the need for frequent visits to healthcare facilities. Additionally, the convenience and ease of use associated with pen injectors can lead to improved patient compliance and adherence to prescribed biologic therapies which fuels the market demand.

Restraint:

Limited compatibility with certain medications

Healthcare providers may be hesitant to prescribe or recommend pen injectors if they are not compatible with a wide range of medications. Patients who require multiple medications, some of which are not compatible with the pen injector, may find it inconvenient or burdensome to use different administration methods. This can lead to decreased patient satisfaction and compliance. Manufacturers may miss out on business opportunities with pharmaceutical companies. This could result in lost partnerships and contracts.

Opportunity:

Integration with digital health solutions

Pen injector's integration with digital health solutions offers a range of benefits and applications for both patients and healthcare providers. It allows patients to track and monitor their medication doses. Digital health platforms can send reminders and alerts to patients, prompting them to take their medication at the prescribed times. Based on the data collected, healthcare providers can make informed decisions about medication titration or adjustments to optimize treatment outcomes. Further, it also enhances patient engagement, reduces hospitalizations, and provides insights for specific conditions which boost the market growth.

Threat:

Competition from alternative drug delivery methods

Alternative drug delivery methods, such as oral tablets, inhalers, patches, and even newer technologies like smart pills or implantable devices, offer patients a range of options. Some patients may prefer alternative methods of drug delivery over pen injectors with a fear of needles. Further, certain conditions may respond better to inhalable or oral forms of medication compared to injectables. Additionally, innovation and improvements in alternative methods, making them more attractive to patients and healthcare providers which impedes the market growth.

COVID-19 Impact

The pen injectors market, which is a part of the medical device industry, likely experienced both positive and negative effects during the pandemic. The rise of telemedicine and remote monitoring during the pandemic may have influenced the adoption of pen injectors, as they are conducive to self-administration and remote monitoring of chronic conditions. Economic uncertainty and shifts in healthcare priorities may have led to market consolidation. The epidemic has affected the vaccination rates, and the emergence of new variants.

The diabetes segment is expected to be the largest during the forecast period

The diabetes segment is estimated to have a lucrative growth. Pen injectors allow for precise and accurate dosing of insulin, ensuring that individuals receive the correct amount of medication. Pen injectors are compact, lightweight, and easy to carry, making them convenient for individuals who need to administer insulin on the go. They use fine-gauge needles, which can result in less pain and discomfort during injection. Its user-friendly nature, customizable dosing and discreet administration propels the segment demand.

The home-care settings segment is expected to have the highest CAGR during the forecast period

The home-care settings segment is anticipated to witness the highest CAGR growth during the forecast period, due to its convenience and effectiveness. Pen injectors are designed to be user-friendly, often featuring simple mechanisms for loading and administering medication. They are compact and portable, allowing patients to administer their medication at home or on the go. It empowers patients to take control of their own medication regimen. These aspects accelerate the segment growth.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to increasing prevalence of chronic diseases and rising healthcare expenditure. Countries like China, Japan, India, South Korea and Australia are major markets for healthcare products and devices due to their large and diverse population. The region has the presence of major key players such as Sanofi, Novo Nordisk and Sun Pharmaceutical Industries. Additionally, some governments in the Asia Pacific region have implemented policies and initiatives to promote the use of advanced medical devices, which has positively impacted the market for pen injectors.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to the increasing prevalence of chronic diseases, the trend towards self-administration of drugs, and advancements in pen injector technology. Increasing incidence of diabetes and growing obese population is contributing toward market growth. The market is competitive with several key players such as Antares Pharma and Becton, Dickinson & Company. Further, technological advancements, the presence of a wide distribution network and increase in geriatric population, which require safer delivery devices, are other factors driving the North America market.

Key players in the market

Some of the key players profiled in the Pen Injectors Market include: AstraZeneca, Becton, Dickinson and Company, Merck Group, Pfizer Inc., Eli Lilly and Company, Novartis AG, Sanofi, Novo Nordisk A/S, Biocon, Medtronic, Terumo Medical Corporation, Sun Pharmaceutical Industries Limited, GlaxoSmithKline PLC, Mylan N.V., Novo Nordisk, Owen Mumford Limited and Phillips-Medisize.

Key Developments:

In February 2023, Phillips-Medisize announced an addition to its portfolio of drug delivery devices, with its pen injector platform that is described as being more affordable to produce. The pen injector has been designed to match user expectation and experiences with disposable pen products, the company added.

In January 2023, Sun Pharmaceutical Industries Ltd launched its Phenobarbital sodium injection, SEZABY for treatment of neonatal seizures in the US. SEZABY is the first and only product approved by the US Food and Drug Administration (USFDA) for the treatment of neonatal seizures in term and preterm infants, Sun Pharma said in a regulatory filing.

In September 2022, Medtronic announced the European launch of its Smart MDI system, which combines personalized insulin dosing information from the InPen™ smart insulin pen with the power of predictive glucose alerts from the Guardian™ 4 smart continuous glucose monitoring (CGM) system.

Types Covered:

  • Disposable
  • Reusable

Dosages Covered:

  • Fixed Dosage
  • Variable Dosage
  • Half-Unit Dosage
  • Specialized Dosage
  • Other Dosages

Therapies Covered:

  • Diabetes
  • Growth Hormone
  • Osteoporosis
  • Fertility
  • Arthritis
  • Cancer
  • Multiple Sclerosis
  • Autoimmune Diseases
  • Anaphylaxis
  • Cardiovascular Diseases
  • Other Therapies

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Stores
  • Drug Stores

End Users Covered:

  • Home-care Settings
  • Hospital & Clinics

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Pen Injectors Market, By Type

  • 5.1 Introduction
  • 5.2 Disposable
  • 5.3 Reusable

6 Global Pen Injectors Market, By Dosage

  • 6.1 Introduction
  • 6.2 Fixed Dosage
  • 6.3 Variable Dosage
  • 6.4 Half-Unit Dosage
  • 6.5 Specialized Dosage
  • 6.6 Other Dosages

7 Global Pen Injectors Market, By Therapy

  • 7.1 Introduction
  • 7.2 Diabetes
    • 7.2.1 Insulin
    • 7.2.2 Glucagon-Like-Peptide-1 (GLP-1)
  • 7.3 Growth Hormone
  • 7.4 Osteoporosis
  • 7.5 Fertility
  • 7.6 Arthritis
  • 7.7 Cancer
  • 7.8 Multiple Sclerosis
  • 7.9 Autoimmune Diseases
  • 7.10 Anaphylaxis
  • 7.11 Cardiovascular Diseases
  • 7.12 Other Therapies

8 Global Pen Injectors Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Online Stores
  • 8.5 Drug Stores

9 Global Pen Injectors Market, By End User

  • 9.1 Introduction
  • 9.2 Home-care Settings
  • 9.3 Hospital & Clinics

10 Global Pen Injectors Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 AstraZeneca
  • 12.2 Becton, Dickinson and Company
  • 12.3 Merck Group
  • 12.4 Pfizer Inc.
  • 12.5 Eli Lilly and Company
  • 12.6 Novartis AG
  • 12.7 Sanofi
  • 12.8 Novo Nordisk A/S
  • 12.9 Biocon
  • 12.10 Medtronic
  • 12.11 Terumo Medical Corporation
  • 12.12 Sun Pharmaceutical Industries Limited
  • 12.13 GlaxoSmithKline PLC
  • 12.14 Mylan N.V.
  • 12.15 Novo Nordisk
  • 12.16 Owen Mumford Limited
  • 12.17 Phillips-Medisize

List of Tables

  • Table 1 Global Pen Injectors Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Pen Injectors Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Pen Injectors Market Outlook, By Disposable (2021-2030) ($MN)
  • Table 4 Global Pen Injectors Market Outlook, By Reusable (2021-2030) ($MN)
  • Table 5 Global Pen Injectors Market Outlook, By Dosage (2021-2030) ($MN)
  • Table 6 Global Pen Injectors Market Outlook, By Fixed Dosage (2021-2030) ($MN)
  • Table 7 Global Pen Injectors Market Outlook, By Variable Dosage (2021-2030) ($MN)
  • Table 8 Global Pen Injectors Market Outlook, By Half-Unit Dosage (2021-2030) ($MN)
  • Table 9 Global Pen Injectors Market Outlook, By Specialized Dosage (2021-2030) ($MN)
  • Table 10 Global Pen Injectors Market Outlook, By Other Dosages (2021-2030) ($MN)
  • Table 11 Global Pen Injectors Market Outlook, By Therapy (2021-2030) ($MN)
  • Table 12 Global Pen Injectors Market Outlook, By Diabetes (2021-2030) ($MN)
  • Table 13 Global Pen Injectors Market Outlook, By Insulin (2021-2030) ($MN)
  • Table 14 Global Pen Injectors Market Outlook, By Glucagon-Like-Peptide-1 (GLP-1) (2021-2030) ($MN)
  • Table 15 Global Pen Injectors Market Outlook, By Growth Hormone (2021-2030) ($MN)
  • Table 16 Global Pen Injectors Market Outlook, By Osteoporosis (2021-2030) ($MN)
  • Table 17 Global Pen Injectors Market Outlook, By Fertility (2021-2030) ($MN)
  • Table 18 Global Pen Injectors Market Outlook, By Arthritis (2021-2030) ($MN)
  • Table 19 Global Pen Injectors Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 20 Global Pen Injectors Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
  • Table 21 Global Pen Injectors Market Outlook, By Autoimmune Diseases (2021-2030) ($MN)
  • Table 22 Global Pen Injectors Market Outlook, By Anaphylaxis (2021-2030) ($MN)
  • Table 23 Global Pen Injectors Market Outlook, By Cardiovascular Diseases (2021-2030) ($MN)
  • Table 24 Global Pen Injectors Market Outlook, By Other Therapies (2021-2030) ($MN)
  • Table 25 Global Pen Injectors Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 26 Global Pen Injectors Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 27 Global Pen Injectors Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 28 Global Pen Injectors Market Outlook, By Online Stores (2021-2030) ($MN)
  • Table 29 Global Pen Injectors Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 30 Global Pen Injectors Market Outlook, By End User (2021-2030) ($MN)
  • Table 31 Global Pen Injectors Market Outlook, By Home-care Settings (2021-2030) ($MN)
  • Table 32 Global Pen Injectors Market Outlook, By Hospital & Clinics (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.